122 related articles for article (PubMed ID: 3839751)
21. Combination chemotherapy in advanced ovarian carcinoma.
Amadori D; Ravaioli A; Maltoni M; Ridolfi R; Gentilini P; Giunchi DC; Frassineti L; Falcini F; Amadori M
Tumori; 1986 Oct; 72(5):519-24. PubMed ID: 3798574
[TBL] [Abstract][Full Text] [Related]
22. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
23. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy in recurrent epithelial ovarian cancer (EOC): an analysis of prognostic factors.
Shamsunder S; Kumar L; Gupta S; Kumar S; Bhatla N; Singh R; Kochupillai V
J Obstet Gynaecol Res; 2000 Jun; 26(3):215-22. PubMed ID: 10932985
[TBL] [Abstract][Full Text] [Related]
25. Hexamethylmelamine, cyclophosphamide, adriamycin, cis-platinum chemotherapy as initial and second-line treatment of advanced ovarian carcinoma.
Richman CM; Podczaski E; Weiser PA; Herbst AL
Oncology; 1986; 43(1):12-7. PubMed ID: 3079898
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.
Di Re F; Bohm S; Oriana S; Spatti GB; Zunino F
Cancer Chemother Pharmacol; 1990; 25(5):355-60. PubMed ID: 2306797
[TBL] [Abstract][Full Text] [Related]
27. Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.
Razis DV; Poulakou E; Petounis A; Papadimitriou G; Kosmides P; Delides G
Oncology; 1982; 39(4):205-8. PubMed ID: 6806735
[TBL] [Abstract][Full Text] [Related]
28. Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial.
Sessa C; Bolis G; Colombo N; D'Incalci M; Mermillod B; Valente I; Mangioni C
Cancer Chemother Pharmacol; 1985; 14(3):222-8. PubMed ID: 3922639
[TBL] [Abstract][Full Text] [Related]
29. A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group.
Ngan HY; Choo YC; Cheung M; Wong LC; Ma HK; Collins R; Fung C; Ng CS; Wong V; Ho HC
Chemotherapy; 1989; 35(3):221-7. PubMed ID: 2766862
[TBL] [Abstract][Full Text] [Related]
30. cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma.
Carmo-Pereira J; Costa FO; Henriques E
Cancer Chemother Pharmacol; 1983; 10(2):100-3. PubMed ID: 6403254
[TBL] [Abstract][Full Text] [Related]
31. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
Anderson H; Wagstaff J; Crowther D; Swindell R; Lind MJ; McGregor J; Timms MS; Brown D; Palmer P
Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin and cyclophosphamide in advanced ovarian carcinoma: activity and toxicity of an ambulatory regimen.
Zambetti M; Gianni L; Di Re F; Spatti G; Fontanelli R; Escobedo A; De Palo G; Bonadonna G
Am J Clin Oncol; 1990 Jun; 13(3):199-203. PubMed ID: 2161174
[TBL] [Abstract][Full Text] [Related]
33. Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer.
Bruckner HW; Cohen CJ; Goldberg JD; Kabakow B; Wallach RC; Deppe G; Reisman AZ; Gusberg SB; Holland JF
Am J Obstet Gynecol; 1983 Mar; 145(6):653-8. PubMed ID: 6402934
[TBL] [Abstract][Full Text] [Related]
34. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study.
Omura G; Blessing JA; Ehrlich CE; Miller A; Yordan E; Creasman WT; Homesley HD
Cancer; 1986 May; 57(9):1725-30. PubMed ID: 3513943
[TBL] [Abstract][Full Text] [Related]
35. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
Greco FA; Johnson DH; Hainsworth JD
Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
[TBL] [Abstract][Full Text] [Related]
36. Antiemetic combination for PAC (cisplatin-adriamycin-cyclophosphamide) chemotherapy-induced emesis in ovarian cancer.
Martin-Jimenez M; Diaz-Rubio E; Gonzalez Larriba JL; Sangro B
Eur J Gynaecol Oncol; 1987; 8(2):98-102. PubMed ID: 3552683
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy of advanced non-small-cell lung cancer with cyclophosphamide, adriamycin, methotrexate, and procarbazine versus cisplatin and etoposide. A randomized study.
Veronesi A; Magri MD; Tirelli U; Carbone A; Mazza F; Franceschi S; Talamini R; Ardizzoni A; Canobbio L; Rosso R
Am J Clin Oncol; 1988 Oct; 11(5):566-71. PubMed ID: 2845769
[TBL] [Abstract][Full Text] [Related]
38. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer.
Di Re F; Bohm S; Oriana S; Spatti GB; Pirovano C; Tedeschi M; Zunino F
Ann Oncol; 1993 Jan; 4(1):55-61. PubMed ID: 8435364
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy for stage III-IV ovarian cancer: the CAP-regimen in previously untreated patients.
Meerpohl HG; Pfleiderer A; Kleine W; Teufel G
Onkologie; 1982 Oct; 5(5):238-41. PubMed ID: 6760025
[TBL] [Abstract][Full Text] [Related]
40. Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract.
Khandekar JD; Elson PJ; DeWys WD; Slayton RE; Harris DT
J Clin Oncol; 1985 Apr; 3(4):539-45. PubMed ID: 3884746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
